Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Arthritis & Rheumatology"

Gout Flares & the NLRP3 Inflammasome

Katie Robinson  |  May 30, 2025

Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as new treatment option.

New Editor in Chief Has Expansive Vision for Arthritis & Rheumatology

Leslie Mertz, PhD   |  May 30, 2025

Incoming Arthritis & Rheumatology Editor-in-Chief Dr. S. Louis Bridges Jr., MD, PhD, discusses his path to rheumatology and outlines his vision for the journal.

Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View

Arthritis & Rheumatology  |  May 27, 2025

Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.

A&R Editor-in-Chief Daniel H. Solomon, MD, MPH, Reflects on the Journal, His Role & Its Future

Leslie Mertz, PhD  |  February 28, 2025

New clinical features, opinion pieces and much more—outgoing Arthritis & Rheumatology Editor-in-Chief Daniel H. Solomon, MD, MPH, discusses how the journal has evolved and where it’s going.

Metabolic Syndrome & RA Treatment Response

Arthritis & Rheumatology  |  February 26, 2025

Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.

Editor's Pick

Weathering the Cytokine Storm: Macrophage Activation Syndrome in Adults & Children

Katie Robinson  |  December 18, 2024

Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.

Lung Cancer in RA & RA-ILD

Arthritis & Rheumatology  |  November 25, 2024

Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.

Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease

Anurag Goel, Joshua Tanzer & Vinit Gilvaz  |  November 7, 2024

Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…

Autoantibodies Illuminate Lupus Nephritis

Arthritis & Rheumatology  |  October 28, 2024

Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.

Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis

Arthritis & Rheumatology  |  September 20, 2024

Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.

  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences